Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus enzalutamide vs enzalutamide in mCRPC
CTR20170690Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roche. Started Oct 2017; status: terminated.
02
Drugs
atezolizumabenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20170690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170690.